97117 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus; Retroviridae, e.g. leukemia viruses; Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
BISPECIFIC ANTIBODIES PROMOTE NATURAL KILLER CELL-MEDIATED ELIMINATION OF HIV-1 RESERVOIR CELLS
#2CAR for Treatment of HIV Infection
#3LYSOSOMAL DEGRADATION
#4ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#5MULTISPECIFIC ANTIBODIES TARGETING MULTIPLE EPITOPES ON THE HIV-1 ENVELOPE
#6METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES
#7BROADLY NEUTRALIZING ANTIBODIES THAT TARGET HIV ENV V3 N-GLYCANS
#8BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION
#9COMBINATION THERAPY
#10HIV Treatment Compositions And Methods
#11Antigen Binding Proteins
#12ANTIBODIES SPECIFICALLY BINDING PD-1, TIM-3 OR PD-1 AND TIM-3 AND THEIR USES
#13NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
#14NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE
#15BISPECIFIC ANTIBODIES TO HIV-1 ENV AND THEIR USE
#16NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
#17SPIKE FURIN CLEAVAGE IS A SARS-COV-2 TARGETING STRATEGY TO BREAK THE CHAIN OF INFECTION CYCLE
#18Combination of Broadly Neutralizing HIV Antibodies and Viral Inducers
#19T-CELLS FOR ANTI-HIV CAR-T THERAPY AND METHODS OF USE
#20BROADLY NEUTRALIZING ANTI-HIV ANTIBODIES AND EPITOPE THEREFOR
#21ENGINEERING B CELLS TO EXPRESS CHIMERIC ANTIGEN RECEPTORS (CARS) AND USES THEREOF FOR T CELL INDEPENDENT ACTIVATION
#22BISPECIFIC ANTIBODIES AGAINST HER2
#23ANTIBODIES TARGETING HIV ESCAPE MUTANTS
#24MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE
#25PROTEINACEOUS COMPOUND FOR GENERATING SPECIFIC CYTOTOXIC T-CELL EFFECT
#26Chimeric Antigen Receptor-T Cells Targeting HIV-Infected Cells
#27METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH GP120 V3 GLYCAN-DIRECTED ANTIBODIES
#28TARGETED DRUG DELIVERY-RELEASE AND KILLING OF DRUG RESISTANT TUMORS AND PATHOGENS
#29HIV-BINDING PEPTIDES AND MEDICAL USE THEREOF
#30COMBINATION THERAPIES FOR HIV INFECTIONS AND USES THEREOF
#31HIGHLY ACTIVE AGONISTIC CD4 BINDING SITE ANTI-HIV ANTIBODIES (HAADS) COMPRISING MODIFIED CDRH2 REGIONS THAT IMPROVE CONTACT WITH GP120
#32MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES
#33Antibody Biopharmaceutical Formulations Including Polymer Excipients
#34BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV
#35COMPOSITIONS AND METHODS FOR TREATING HIV/AIDS WITH IMMUNOTHERAPY
#36Chimeric Antigen Receptor-Modified NK-92 Cells
#37DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS
#38GENE SEQUENCE CONSTRUCT FOR GENE THERAPY OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION
#39Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#40MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS
#41NUCLEIC ACID CONSTRUCT FOR AIDS GENE THERAPY
#42Human Immunodeficiency Virus Neutralizing Antibodies And Methods Of Use Thereof
#43ANTIGEN BINDING POLYPEPTIDES
#44Chimeric Antigen Receptor-Modified NK-92 Cells
#45HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF
#46ANTIGEN BINDING PROTEINS
#47HUMAN IMMUNODEFICIENCY VIRUS (HIV) ANTIGENS AND EPITOPES AND PROTEINS THAT BIND THERETO
#48METHODS TO IDENTIFY IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
#49COMPOSITIONS AND METHODS FOR PROPHYLAXIS OF HIV
#50METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES
#51NUCLEIC ACIDS ENCODING HIV NEUTRALIZING ANTIBODIES AND USES THEREOF
#52HUMAN BROADLY NEUTRALIZING ANTIBODIES AGAINST THE MEMBRANE-PROXIMAL EXTERNAL REGION OF HIV ENV FOR VACCINE DESIGN AND INTERVENTION
#53BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV
#54RAPID ELICITATION OF BROADLY NEUTRALIZING BOVINE ANTIBODIES TO HIV ENV
#55Bispecific antigen-binding molecules and methods of use
#56DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES
#57CHIMERIC RECEPTOR CONSTRUCTS FOR NK CELLS
#58Antibodies that target HIV GP120 and methods of use
#59HIV treatment compositions and methods
#60HUMANIZED OR CHIMERIC CD3 ANTIBODIES
#61Antibody biopharmaceutical formulations including polymer excipients
#62Human immunodeficiency virus neutralizing antibodies and methods of use thereof
#63INERT FORMAT
#64Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#65IMMUNOSTIMULATORY ADJUVANTS
#66ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#67Broadly-Neutralizing HIV Antibodies
#68METHODS FOR IDENTIFICATION OF LIGAND-BLOCKING ANTIBODIES AND FOR DETERMINING ANTIBODY POTENCY
#69BROADLY NEUTRALIZING AND POTENT ANTIBODIES AGAINST HIV
#70CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS AND THEIR USE IN CAR-T CELLS
#71ANTIGEN BINDING POLYPEPTIDES, ANTIGEN BINDING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF
#72Recombinant HIV-1 envelope proteins and their use
#73ENGINEERED ANTIBODIES
#74Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
#75COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN STRUCTURE DETERMINATION
#76Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof
#77CELL-RECEPTOR TARGETED EXOSOMES
#78CAR for Treatment of HIV Infection
#79METHODS FOR INCREASING THE DIVERSITY OF MONOCLONAL ANTIBODIES PRODUCED AGAINST AN ANTIGEN
#80Neutralizing antibodies to GP120 and their use
#81Multi-specific antigen binding molecules targeting HIV and methods of use
#82Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
#83DNA ANTIBODY CONSTRUCTS AND METHOD OF USING SAME
#84BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV
#85METHODS FOR TREATING VIRAL INFECTIONS
#86Chimeric antigen receptor-modified NK-92 cells
#87METHODS FOR IDENTIFICATION OF LIGAND-BLOCKING ANTIBODIES AND FOR DETERMINING ANTIBODY POTENCY
#88COMPOSITIONS INCLUDING IGG FC MUTATIONS AND USES THEREOF
#89MHC class I epitope delivering polypeptides
#90ANTIBODIES AND THE USES THEREOF
#91De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals
#92HIV BINDING AGENTS
#93Immunological Reagents
#94Multispecific Anti-HIV Antibodies
#95Bivalent, bispecific binding proteins for prevention or treatment of HIV infection
#96Methods to identify immunogens by targeting improbable mutations
#97Immunological Reagents
#98HIV-1 gp120 CD4 binding site antibodies targeting HIV escape mutants
#99METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
#100DNA Antibody Constructs And Method Of Using Same
#101Compositions and methods for identifying and sorting antigen-specific B cells
#102USE OF MODIFIED HIV-1 FOR GENERATING FULLY HUMAN ANTIBODIES
#10310E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use
#104ANTIBODIES THAT TARGET HIV GP120 AND METHODS OF USE
#105HIV treatment compositions and methods
#106Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor
#107Broadly-neutralizing anti-HIV antibodies
#108METHOD FOR ENGINEERING IMMUNOGLOBULINS
#109INTRATHECAL ADMINISTRATION OF ADENO-ASSOCIATED-VIRAL VECTORS FOR GENE THERAPY
#110Virtual assistant focused user interfaces
#111Recombinant HIV Env polypeptides and their use
#112ANTI-HIV ANTIBODIES
#113IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE
#114BISPECIFIC ANTIBODIES AGAINST HER2
#115NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
#116ENGINERRED ANTIBODIES TO HIV ENV
#117Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
#118Chimeric antigen receptor-modified NK-92 cells
#119Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
#120MHC class I epitope delivering polypeptides
#121Optimized gp41-Binding Molecules and Uses Thereof
#122DIMERIC PROTEIN WITH TRIPLE MUTATIONS
#123Human immunodeficiency virus neutralizing antibodies and methods of use thereof
#124Compositions and methods for treating HIV/AIDS with immunotherapy
#125Bispecific CD16-binding molecules and their use in the treatment of disease
#126Human immunodeficiency virus neutralizing antibodies
#127Epitope restriction for antibody selection
#128Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
#129Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
#130Bispecific HIV-1-neutralizing antibodies
#131Neutralizing antibodies to HIV-1 Env and their use
#132Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#133ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#134CELL-TARGETING MOLECULES COMPRISING PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CARBOXY-TERMINAL MOIETIES
#135HIV Binding Agents
#136Multispecific antibodies that target HIV GP120 and CD3
#137Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
#138Methods of identifying HIV patients sensitive to therapy with GP120 V3 glycan-directed antibodies
#139Bispecific molecules comprising an HIV-1 envelope targeting arm
#140Inert format
#141Methods and compositions for treating and preventing HIV
#142Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis
#143Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
#144Combination of broadly neutralizing HIV antibodies and viral inducers
#145Immunoconjugates with an intracellularly-cleavable linkage
#146Bispecific antibodies against HER2 and CD3
#147Heterodimeric antibody Fc-containing proteins and methods for production thereof
#148Broadly neutralizing antibodies against HIV
#149Modified non-natural NKG2D ligands that selectively deliver attached heterologous molecules to non-natural NKG2D receptors on car-cells
#150NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
#151METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE AND DIAGNOSTIC DEVELOPMENT
#152Antibodies that target HIV GP120 and methods of use
#153Humanized or chimeric CD3 antibodies
#154Broadly Neutralizing Monoclonal Antibodies Against HIV-1 V1V2 Env Region
#155REAGENTS FOR INDUCING AN IMMUNE RESPONSE
#156Methods of making active antibodies from biological fluids
#157Compositions and methods for identifying and sorting antigen-specific B cells
#158BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV
#159Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
#160Rapid elicitation of broadly neutralizing antibodies to HIV Env
#161Multivalent glycopeptides that tightly bind to target proteins
#162METHODS AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSION
#163Nucleic acids encoding broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 ENV subunits
#164Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies in subjects with low viral loads
#165HUMANIZED OR CHIMERIC CD3 ANTIBODIES
#166Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
#167Immunoconjugates with an intracellularly-cleavable linkage
#168Directed evolution of multivalent glycopeptides that tightly bind to target proteins
#169Methods and compositions for treating and preventing HIV
#170Polyclonal antibodies produced using HIV-1 trimeric envelope glycoprotein subunits
#171Bivalent, bispecific binding proteins for prevention or treatment of HIV infection
#172METHODS FOR INCREASING THE DIVERSITY OF MONOCLONAL ANTIBODIES PRODUCED AGAINST AN ANTIGEN
#173Methods to identify immunogens by targeting improbable mutations
#174Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
#175CONSTRUCTION AND APPLICATION OF RECOMBINANT GENE FOR CHIMERIC ANTIGEN RECEPTOR FOR TREATING HIV INFECTION
#176Recombinant HIV-1 envelope proteins and their use
#177HIV treatment compositions and methods
#178Compositions containing anti-HIV ostrich antibodies
#179VC-CAR molecule and use thereof in removing HIV-1 infected cells
#180ANTIBODY COMPOSITION-PRODUCING CELL
#181HIV binding agents
#182Broadly-neutralizing anti-HIV antibodies
#183Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#184ANTIBODY-DRUG CONJUGATES AND THERAPEUTIC METHODS USING THE SAME
#185TUMOR ANTIGEN SPECIFIC ANTIBODIES AND TLR3 STIMULATION TO ENHANCE THE PERFORMANCE OF CHECKPOINT INTERFERENCE THERAPY OF CANCER
#186Recombinant HIV epitopes and uses thereof
#187Bispecific antigen-binding molecules and methods of use
#188Antiretroviral drug targeting human endogenous retrovirus
#189Human immunodeficiency virus neutralizing antibodies
#190Methods for protein modification in pharmaceutical applications
#191Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
#192Compositions and methods for treating HIV/AIDS with immunotherapy
#193Broadly cross-reactive HIV-1-specific antibodies for prevention and treatment of HIV
#194Methods and compositions for treating and preventing HIV
#195Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#196Immunoconjugates with an intracellularly-cleavable linkage
#197Methods to identify prime and boost immunogens for use in a B cell lineage-based vaccination protocol
#198MHC Class I Epitope Delivering Polypeptides
#199HIV DIAGNOSTIC METHOD USING CD4 AND CD8 CELL INFORMATION
#200Immunoglobulins directed to bacterial, viral and endogenous polypetides
#201HIV-1 vaccine
#202Immunological reagents
#203DNA antibody constructs and method of using same
#204Neutralizing antibodies to HIV-1 GP41 and their use
#205Immunological reagents
#206NON-HUMAN ANIMALS HAVING A MUTANT KYNURENINASE GENE
#207Generation of human anti-HIV-1 ENV monoclonal antibodies with neutralizing activity from humanized mice infected with HIV-1
#208TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION
#209Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
#210Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#211ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#212Antibody and antibody-containing composition
#213Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein
#214Broadly neutralizing antibodies against HIV-1 and use thereof
#215Therapeutic peptides and vaccines
#216Multispecific antibodies that target HIV GP120 and CD3
#217Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
#218DNA ANTIBODY CONSTRUCTS AND METHOD OF USING SAME
#219Intrathecal administration of adeno-associated-viral vectors for gene therapy
#220Immunoconjugates with an intracellularly-cleavable linkage
#221Nucleic acids encoding human immunodeficiency virus type 1 (HIV-1) N-terminal deleted gp120 immunogens and methods of use
#222Neutralizing antibodies to gp120 and their use
#223Broadly neutralizing antibody directed against HIV-1 GP140
#224Synthesizing vaccines, immunogens, and antibodies
#225Anti-HIV dual specificity antibodies and methods of HIV treatment
#226Methods of making heavy chain only antibodies using transgenic animals
#227Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with gp120
#228Bispecific HIV-1-neutralizing antibodies
#229HIV-1 GP120 CD4 binding site antibodies targeting HIV escape mutants
#230Tri-specific antibodies for HIV therapy
#231Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
#232Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
#233Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
#234Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
#235Bispecific molecules comprising an HIV-1 envelope targeting arm
#236METHODS AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSION
#237Sensor systems for target ligands and uses thereof
#238Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
#239Bispecific multivalent fusion proteins
#240Stabilized single human CD4 domains and fusion proteins
#241HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies)
#242Human immunodeficiency virus neutralizing antibodies and methods of use thereof
#243HIV-1 neutralizing antibodies and uses thereof (V3 antibodies)
#244Antibody and antibody-containing composition
#245Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody
#246Compositions for preventing and/or treating an infection by an HIV-1 virus
#247Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat domain peptides
#248Neutralizing GP41 antibodies and their use
#249METHOD FOR ENGINEERING IMMUNOGLOBULINS
#250BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3
#251Neutralizing antibodies to HIV-1 and their use
#252IMMUNOGLOBULINS WITH REDUCED AGGREGATION
#253Antibodies With Simultaneous Subsite Specificities To Protein and Lipid Epitopes
#254Methods for the diagnosis of cancer through detection of human endogenous retrovirus WL (HERV-WL) envelope expression
#255Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
#256Stable immunogen based on inner domain of HIV-1 gp120 for inducing immunity against HIV
#257Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
#258Chimeric antigen receptors to control HIV infection
#259Immunoconjugates with an intracellularly-cleavable linkage
#260PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER
#261DNA antibody constructs and method of using same
#262Soluble engineered monomeric Fc
#263Bispecific HIV-1 neutralizing antibodies
#264Immunoconjugates with an intracellularly-cleavable linkage
#265Heterodimeric antibody Fc-containing proteins and methods for production thereof
#266Recombinant HIV-1 envelope proteins and their use
#267Inhibitors of HIV-1 entry and methods of use thereof
#268Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
#269Immunological reagents
#270Combination of broadly neutralizing HIV antibodies and viral inducers
#271PEPTIDES MIMICKING HIV-1 VIRAL EPITOPES IN THE V2 LOOP FOR THE GP120 SURFACE ENVELOPE GLYCOPROTEIN
#272Human immunodeficiency virus neutralizing antibodies
#273METHODS FOR INCREASING THE DIVERSITY OF MONOCLONAL ANTIBODIES PRODUCED AGAINST AN ANTIGEN
#274POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
#275Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
#276Anti-PD-L1 antibodies, compositions and articles of manufacture
#277Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
#278Antiretroviral Drug Targeting Human Endogenous Retrovirus
#279Engineered antibody constant domain molecules
#280Immunoconjugates with an intracellularly-cleavable linkage
#281Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
#282Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
#283Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region
#284CD4-MIMETIC SMALL MOLECULES SENSITIZE HUMAN IMMUNODEFICIENCY VIRUS TO VACCINE-ELICITED ANTIBODIES
#285Methods for protein modification in pharmaceutical applications
#286Antibody composition-producing cell
#287Non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection
#288SCREENING FOR TARGET-SPECIFIC AFFINITY BINDERS
#289Antibody and antibody-containing composition
#290DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS
#291Humanized or chimeric CD3 antibodies
#292Neutralizing GP41 antibodies and their use
#293HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies
#294Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates
#295Drug target site within GP120 of HIV
#296DNA antibody constructs and method of using same
#297Directed evolution of multivalent glycopeptides that tightly bind to target proteins
#298Multivalent glycopeptides that tightly bind to target proteins
#299HIV-1 broadly neutralizing antibodies
#300Anti-HIV dual specificity antibodies and methods of HIV treatment